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INTRODUCTION AND OBJECTIVES: A potential risk of significant competing causes of mortality in men submitted to salvage radiation therapy (SRT) might be present. We aimed at reporting the natural history of patients treated with SRT from a large multiinstitutional series.
METHODS: The study included 715 patients who received SRT at six tertiary referral centres for either PSA rising after RP, or PSA persistence after surgery that was defined as PSA level !0.1 ng/ml at 1 month after surgery. The irradiation of the pelvic lymph nodes area was left at the discretion of the treating physician. The study outcomes were cancer-specific (CSM) and other cause mortality (OCM). Cox regression analyses were used to predict the risk of CSM and OCM. Predictors consisted of patient age, pT stage ( pT3a vs. !pT3b), pathologic Gleason ( 7 vs. !8), surgical margins (negative vs. positive), PSA level at SRT, and concomitant hormonal therapy (HT) administration. Competing-risks Poisson regression methodologies were performed.
RESULTS: Median patient age and PSA level at SRT were 66 years and 0.30 ng/ml, respectively. At a median follow-up of 102 months (inter-quartile range: 61, 135), local recurrence was detected in 14 (2.0%) patients, whereas 30 (4.3%), 16 (2.3%), 64 (9.2%), and 13 (1.9%) developed pelvic, retroperitoneal, skeletal, and visceral metastasis, respectively. Overall, 154 patients were died at last follow-up: 39 patients succumbed to prostate cancer, and 115 died from other cause. At 10 years follow-up, CSM and OCM rates were 13% and 37%, respectively. At multivariable competing-risks regression analyses, pathologic stage !pT3b (HR: 3.16, p¼0.006) and Gleason score ¼8 (HR: 3.56, p¼0.003) were independent predictors of CSM, after accounting for the risk of dying from other cause. Conversely, age (HR: 1.08, p<0.0001) and concomitant HT (HR: 1.15, p¼0.001) represented independent predictors of OCM, after accounting for the risk of dying from prostate cancer. When patients were stratified by age ( 65 vs. >65), the risk of OCM at 10 years was significantly higher in older patients (77% vs. 50%, p<0.0001).
CONCLUSIONS: This is the first study assessing the long-term natural history of SRT after accounting for the risk of OCM. We showed that roughly a third of men submitted to SRT died from other cause rather than from PCa and this rate increased in older men receiving concomitant HT. These results should be taken into account when deciding on the use of SRT after radical prostatectomy according to each patient profile in order to avoid potential overtreatment. 
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INTRODUCTION AND OBJECTIVES:
The role of postprostatectomy radiation therapy (RT) in patients with pN1 prostate cancer is still under debate. However, whether adjuvant RT (aRT) is equal to early salvage RT (esRT) at long term in this setting is still unknown. In this study, we aimed at comparing the long-term effectiveness of aRT versus esRT.
METHODS: Using a multi-institutional cohort from six tertiary referral centres, we identified 171 pN1 patients who were treated with radical prostatectomy and pelvic lymph node dissection. Patients were stratified into two groups: aRT (Group 1) versus initial observation followed by esRT in case of PSA relapse (Group 2). Specifically, aRT was administered at undetectable PSA level within 6 months after RP, whereas esRT was administered at a PSA level 0.5 ng/ml. The clinical target volume included the pelvic lymph nodes area, prostatic and seminal vesicle bed in all patients receiving RT. The evaluated outcomes were metastasis-free and overall survival. Multivariable Cox regression analyses tested the association between groups (aRT vs. observation AE esRT) and the study outcomes. Covariates consisted of pathologic stage ( pT3a vs. !pT3b), pathologic Gleason score ( 7 vs. !8), and surgical margin status (negative vs. positive).
RESULTS: Overall, 85 (50%) and 86 (50%) patients underwent aRT and initial observation, respectively. Median follow-up was similar among groups: 84 vs. 92 months (p¼0.9). In group 2, 69 (80%) patients experienced PSA relapse and underwent esRT. Patients characteristics were not significantly different in terms of pathologic stage (!pT3b: 60% vs. 53%, p¼0.2), Gleason score (!8: 44% vs. 41%, p¼0.9), and positive surgical margins (59% vs. 55%, p¼0.6). Overall, 26 patients developed distant metastasis with the following distribution: retroperitoneal nodes (n¼5), bone (n¼19), and other organs (n¼2). At last follow-up, 13 patients succumb to prostate cancer and 13 patients died for other cause. Metastasis-free survival (67% vs. 72% p¼0.2) and overall survival (78% vs. 74%, p¼0.8) at 8 years after RP were not significantly different among groups. These results were confirmed at multivariable analyses for both distant metastasis (HR: 0.77; p¼0.7) and overall survival (HR: 1.94; p¼0.3).
CONCLUSIONS: At long-term follow-up, timely administration of esRT showed comparable metastasis-free and overall survival to aRT. Even in pN1 patients, esRT may not thus compromise cancer control, while significantly reducing potential over-treatment associated with aRT. Vol. 197, No. 4S, Supplement, Tuesday, May 16, 2017 THE JOURNAL OF UROLOGY â e1363 radical prostatectomy (RP) but does not include multiparametric pelvic MRI (mpMRI). Here, we evaluate the utility of mpMRI in predicting sXRT failure after RP. METHODS: Men undergoing RP at Mayo Clinic from 2003-2015 who had biochemical recurrence and received sXRT were included in a retrospective chart review. Men who underwent prostate cancer treatment prior to RP, received adjuvant XRT, or who were hormone refractory at sXRT were excluded. Patients with mpMRI within 12 months of sXRT were retained. mpMRI lesions were grouped according to location: vesicourethral, seminal vesical (SV) bed / prostate fossa, pelvic nodes, pelvic bones. If no lesion was present, the mpMRI was categorized as negative. Standard descriptive statistics and multivariable cox regression analyses were performed to assess the impact of mpMRI on PSA recurrence after sXRT. Models were adjusted for the variables in the Stephenson Nomogram: PSA at RP, PSA prior to sXRT, PSA doubling time, hormone therapy with sXRT, sXRT dosage, extracapsular extension, SV invasion, pathologic Gleason score, margin status, and pN stage.
Source of
RESULTS: Overall, 473 men had mpMRI prior to sXRT (median PSA at sXRT 0.45ng/ml). Of these, 56.9% (204) had an indeterminate or suspicious lesion on MRI: 25.6% (124) vesicourethral, 27.8% (135) SV bed / prostatic fossa, 7.0% (34) pelvic node, and 0.6% (3) pelvic bone. Median PSA with a visible lesion on mpMRI was 0.45ng/ml. At a median follow up of 42 months after sXRT, 29.3% (142) had PSA recurrence and 14.0% (68) had distant metastasis. Patients without a mpMRI lesion or with a suspicious nodal/bone lesion had higher rates of PSA recurrence at 4 years compared to those with vesicourethral/SV/prostate fossa lesions alone: 39.5% vs 21.9% (p<0.001), Figure 1 . On multivariable analysis, patients without a mpMRI lesion or a suspicious nodal/bone lesion were significantly more likely to have PSA recurrence (HR 2.41, 95% CI 1.52-3.83, p<0.001) after adjusting for variables in the Stephenson Nomogram.
CONCLUSIONS: Pre-sXRT mpMRI is a valuable tool in risk stratifying men undergoing sXRT. The median PSA with a visible lesion on mpMRI was 0.45ng/ml, supporting the use of mpMRI in the early sXRT setting. METHODS: We identified 4,036 patients treated with brachytherapy with or without external beam radiation (EBRT) and/or androgen deprivation therapy (ADT) for their diagnosis of prostate cancer. These patients were treated between 1992 to 2012 at a single institution. Of those patients, 266 had a PSA recurrence as defined by the Phoenix criteria. Of those patients, 92 were found to have distant failure as defined by metastases to bones, visceral organs, or lymph nodes. Kaplan Meier analysis was used to estimate 5-year freedom from distant failure. Univariable and multivariable cox regression analysis was performed to identify factors associated with distant failure.
RESULTS: Median age on presentation for our cohort was 67.5 with a median Gleason score of 7 and PSA of 9.3 ng/ml. We identified a 5-year freedom from distant failure rate of 65.7% with a median follow up of 8.17 years and a median time to BCR of 2.9 years after initial treatment with brachytherapy. Of those patients with distant metastases, 73.9% of patients showed metastases to the bone alone, 16.3% showed metastases to lymph nodes alone, 3.2% showed metastases to visceral organs alone, and 6.5% exhibited multiple sites of metastatic spread simultaneously. On multivariate analysis, Gleason score was significantly associated with increased risk of distant failure (HR¼1.30, P¼.045).
CONCLUSIONS: Patients who experience distant metastatic disease after BCR following brachytherapy are most likely to exhibit metastatic disease to bones, although metastases to visceral organs and lymph nodes were also observed. Gleason score was significantly associated with increased risk of distant failure. Our study is the first to look at patterns of metastatic recurrence within a cohort of patients specifically treated with brachytherapy as the primary modality for prostate cancer therapy. The above findings can be used when counseling patients with prostate cancer who are seeking brachytherapy treatment as well as when considering which imaging modalities to obtain for detection of metastatic disease.
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PD72-09 EARLY OUTCOMES OF FOCAL BRACHYTHERAPY FOR LOCALIZED PROSTATE CANCER: COMPARISON WITH WHOLE GLAND BRACHYTHERAPY.
Victor Srougi*, Eric Barret, Mohammed Baghdadi, Igor Nunes-Silva, Silvia Garcia-Barreras, Gregory Rembeyo, François Rozet, Marc Galiano, Rafael Sanchez-Salas, Jean Cosset, Xavier Cathelineau, Paris, France INTRODUCTION AND OBJECTIVES: Focal brachytherapy (FBT) emerged as a reasonable option to treat patients with favorable prostate cancer (PCa). The aim of this study is to evaluate the early functional and oncological outcomes of FBT in the treatment of localized PCa.
METHODS: A retrospective review was performed at our prospective collected PCa database, searching for patients treated with FBT between 2010 and 2015. A cohort of 100 individuals treated with whole gland brachytherapy (WBT) in the same period was assessed in order to perform a comparison. IPSS, ICS and IIEF5 questionnaires were used to evaluate urinary symptoms, continence and sexual e1364 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Tuesday, May 16, 2017 
